GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » Market Cap

Catalent (Catalent) Market Cap : $9,999 Mil (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Catalent Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Catalent's share price for the quarter that ended in Mar. 2024 was $56.45. Catalent's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 181 Mil. Therefore, Catalent's market cap for the quarter that ended in Mar. 2024 was $10,213 Mil.

Catalent's quarterly market cap declined from Sep. 2023 ($8,241 Mil) to Dec. 2023 ($8,117 Mil) but then increased from Dec. 2023 ($8,117 Mil) to Mar. 2024 ($10,213 Mil).

Catalent's annual market cap increased from Jun. 2021 ($18,434 Mil) to Jun. 2022 ($19,205 Mil) but then declined from Jun. 2022 ($19,205 Mil) to Jun. 2023 ($7,817 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Catalent's Enterprise Value for Today is $14,892 Mil.


Catalent Market Cap Historical Data

The historical data trend for Catalent's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Market Cap Chart

Catalent Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,898.40 11,933.24 18,434.46 19,204.91 7,816.64

Catalent Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,827.80 7,816.64 8,240.93 8,117.41 10,212.60

Competitive Comparison of Catalent's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Catalent's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalent's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Catalent's Market Cap distribution charts can be found below:

* The bar in red indicates where Catalent's Market Cap falls into.



Catalent Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Catalent's Market Cap for the fiscal year that ended in Jun. 2023 is calculated as

Market Cap (A: Jun. 2023 )=Share Price (A: Jun. 2023 )*Shares Outstanding (EOP) (A: Jun. 2023 )
=$43.36*180.273
=$7,817

Catalent's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$56.45*180.914
=$10,213

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Catalent  (NYSE:CTLT) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Catalent Market Cap Related Terms

Thank you for viewing the detailed overview of Catalent's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalent (Catalent) Business Description

Traded in Other Exchanges
Address
14 Schoolhouse Road, Somerset, NJ, USA, 08873
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Executives
David Mcerlane officer: Group President, Biologics C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven Barg director ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
Michelle R Ryan director 214 PARK BLVD S, VENICE FL 34285
John J Greisch director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephanie Okey director C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Frank A Damelio director C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Aristippos Gennadios officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Thomas W Hawkeswood officer: Pres. Pharma Prod Delivery Div C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Patricia Hunt officer: Pres. Consumer Health Div C/O CATALENT, 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson officer: VP, Chief Accounting Officer CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lorenzo Carletti officer: SVP Global Ops Small Molecule C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricardo Pravda officer: SVP, Human Resources C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli officer: See remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Charles Lickfold officer: SVP, CIO C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873

Catalent (Catalent) Headlines

From GuruFocus

Catalent Inc at Stephens Investment Conference Transcript

By GuruFocus Research 01-22-2024

Catalent Inc at Jefferies Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Catalent Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Catalent Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Catalent Inc Investor Presentation Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Catalent Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Catalent Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024